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ABSTRACT 51 
The Mycobacterium tuberculosis (Mtb) Lineage 4 strains CDC1551 and H37Rv develop tolerance 52 
to multiple antibiotics upon macrophage residence. To determine if macrophage-induced 53 
tolerance is a general feature of clinical Mtb isolates, we assessed macrophage-induced drug 54 
tolerance in strains from lineages 1-3, representing the other predominant Mtb strains 55 
responsible for tuberculosis globally. All three lineages developed isoniazid tolerance. While 56 
lineage 1, 3 and 4 strains developed rifampin tolerance, lineage 2 Beijing strains did not. Their 57 
failure to develop tolerance may be explained by their harboring a loss-of-function mutation in 58 
the Rv1258c efflux pump that is linked to macrophage-induced rifampicin tolerance.  59 
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BACKGROUND 62 
 Mycobacterium tuberculosis (Mtb) enters host macrophages shortly after infection and 63 
resides within granulomas, organized macrophage aggregates, for much of its life cycle [1]. 64 
Previously we and others showed that Mtb develops tolerance to multiple first and second line 65 
anti-tubercular drugs soon after infecting macrophages [2-4]. Moreover, we found that 66 
macrophage-induced tolerance to rifampin is mediated via Tap (Rv1258c), a major facilitator 67 
superfamily (MFS) efflux pump [2]. Rv1258c expression is induced when bacteria reside within 68 
cultured human macrophages [5] as well as in bacteria in sputum of TB patients undergoing 69 
treatment with a rifampin-containing regimen [6]. These observations suggest that macrophage 70 
induced tolerance to rifampin mediated by Rv1258c may contribute to drug tolerance observed 71 
in patients. 72 
 Based on genomic differences, Mtb is broadly categorized into multiple lineages 73 
associated with distinct phenotypes with regard to mutability, drug sensitivity, immunogenicity 74 
and virulence [7]. The vast majority of TB worldwide (over 90%) is caused by Mtb lineages 1 75 
(Indo-oceanic), 2 (East Asian), 3 (East African-Indian), and 4 (Euro-American)[7](Supplementary 76 
Figure 1). Our prior observations of macrophage induced tolerance were made in H37Rv and 77 
CDC1551, both of which represent lineage 4 strains. While lineage 4 is perhaps the most widely 78 
distributed geographically, it accounts for only approximately 11% of the global TB burden [7] 79 
(Supplementary Figure 1B). Therefore, we sought to determine whether macrophage-induced 80 
tolerance to isoniazid and rifampin is a shared feature across the other three lineages that are 81 
predominant in high TB-burden areas [7]. In addition, because the Beijing subgroup of lineage 2 82 
strains harbor an inactivating frameshift mutation in Rv1258c [8], we were interested to see if 83 
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they develop rifampin tolerance. Furthermore, Rv1258c also facilitates bacterial growth within 84 




Bacterial strains 89 
The sources and antibiotic susceptibilities of the strains used are detailed in Supplementary 90 
Table 1. Bacteria were grown to mid log-phase in Middlebrook 7H9 medium (Becton Dickinson) 91 
with 0.05% Tween-80 and albumin, dextrose, catalase (Middlebrook ADC Enrichment, Becton 92 
Dickson) prior to infection. 93 
 94 
Macrophage Growth and Infection 95 
THP-1 cells (ATCC) were grown in RPMI 1640, supplemented with 10% FBS and 2mM L-96 
glutamine (Sigma) in 37oC incubator with 5% CO2. 5x105 THP-1 cells were differentiated into 97 
wells of 24-well plates with 100 nM phorbol 12-myristate 13-acetate (PMA, Sigma) for 48 hours, 98 
then media was replaced with fresh media without PMA for 24 hours prior to infection. The 99 
differentiated cells were infected at a multiplicity of infection (MOI) of 1 for 2 hours. Cells were 100 
washed with media and 6 μg/ml streptomycin (Sigma) was added to the media for the 101 
remainder of the intracellular growth to eliminate extracellular bacteria; this was defined as the 102 
start of infection. Media were changed every 48 hours. For intracellular growth inhibition 103 
assays, verapamil HCl (40 μg/ml) (Sigma) was added to the media 48 hours post-infection and 104 
streptomycin was omitted. 105 
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Macrophage-induced tolerance assay 107 
The work flow for this assay is depicted in Supplementary Figure 2. Briefly, THP1 cells were 108 
infected as above and were lysed 2 or 96 hours post-infection to release the bacteria as follows: 109 
Cells were washed briefly once with PBS and then with water. Cells were then incubated with 110 
100 μl of water per well at 37oC for 15 minutes. Then 900 μl of 7H9 medium (supplemented 111 
with Middlebrook ADC and 0.05% Tween-80) was added and the well bottoms scraped with a 112 
pipette tip to ensure complete macrophage lysis, which was microscopically confirmed. Serial 113 
dilutions of 150 µL of cell lysates were made in PBS and plated on 7H10 agar (Becton Dickson) 114 
to obtain the initial colony forming units (CFU). To measure antibiotic killing, 500 µL of cell 115 
lysate was treated with the indicated antibiotic (rifampin 1 μg/ml or isoniazid 0.6 μg/mL, Sigma) 116 
for 48 hours at 37C° before making serial dilutions and plating on 7H10 agar. Percent survival 117 
was determined by dividing the post-antibiotic treatment CFU by the pre-treatment CFU. 118 
 119 
Intracellular growth assay 120 
Infected cells were washed twice with PBS and incubated with 100 μl 0.1% Triton X-100 for 10 121 
minutes. Then 900 μl of PBS was added and the wells scraped with a pipette tip. Dilutions of 122 
cell lysates were plated on 7H10 agar as above. 123 
 124 
Statistical analyses 125 
GraphPad Prism 6.0 was used for statistical analyses. Means were compared via statistical tests 126 
indicated in the figure legends. P values are abbreviated in figures as follows: *, P<0.05; **, 127 
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P<0.01; *** P<0.001, **** P<0.0001. Results from one representative experiment is shown in 128 
each figure. The number of independent experiments is indicated in the figure legends, with 129 
independent experiments defined as experiments setup on different days with different 130 
cultures of bacteria or cells. 131 
 132 
RESULTS 133 
Macrophage-induced antibiotic tolerance occurs across predominant Mycobacterium 134 
tuberculosis lineages 135 
Working at two sites, Seattle Children’s Research Institute (Seattle, USA) and the National 136 
Institute for Research in Tuberculosis (Chennai, India), we used a panel of Mtb strains 137 
representing lineages 1-4 assembled from previously published strains (Seattle site) and from 138 
recent clinical isolates (Chennai site) (Supplementary Table 1). All strains were confirmed to be 139 
susceptible to both isoniazid and rifampin, except strain NIRT203 which was resistant to 140 
isoniazid (Supplementary Table 1). The lineage 2 Beijing strains were confirmed to harbor the 141 
previously described frameshift mutation in Rv1258c, and this mutation was absent in all other 142 
strains, including the lineage 2 non-Beijing isolate M4100A (Supplementary Table 1). 143 
 To assess development of macrophage-induced antibiotic tolerance, THP-1 144 
macrophages were infected with the clinical MTB strains and then lysed at 2 and 96 hours post-145 
infection. Macrophage lysates were treated with antibiotics for 48 hours and tolerance to 146 
antibiotics was assessed by comparing CFU at lysis to the number surviving CFU after antibiotic 147 
treatment (Supplemental Figure 2A). Macrophage-induced tolerance was defined as a 148 
significant (p ≤ 0.05) increase in the fraction of bacteria surviving antibiotic treatment between 149 
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the 2 hour and 96 hour time points. All of the isoniazid susceptible strains developed 150 
macrophage-induced tolerance to isoniazid (Figure 1A and 1B), while NIRT203 was resistant to 151 
killing by isoniazid as expected. Strains from lineages 1, 3 and 4 developed tolerance to rifampin 152 
(Figure 1C). The capacity of lineage 2 Mtb strains to develop tolerance to rifampin was variable. 153 
Both lineage 2 Beijing strains failed to develop rifampin tolerance (Figure 1D). In contrast, 154 
M4100A, a non-Beijing lineage 2 strain, developed macrophage-induced rifampin tolerance 155 
(Figure 1D). 156 
 157 
Lineage 2 Beijing strains grow normally in macrophages 158 
In the CDC1551 strain, Rv1258c mutants not only fail to develop macrophage-induced 159 
rifampin tolerance, but also are defective for early growth in macrophages [2,9]. However, 160 
Beijing strains do not exhibit a macrophage growth defect; indeed, many of them grow more 161 
rapidly in macrophages than non-Beijing isolates [10]. This may be one of the reasons that 162 
some Beijing strains have been found to be hypervirulent in animal infection models and are 163 
spreading globally [7,11]. 164 
 When we tested the two Beijing strains in our panel for their ability to grow in 165 
macrophages, we found that neither manifested an intramacrophage growth defect, confirming 166 
prior findings (Figure 2A). Thus, these Beijing strains have evolved compensatory mechanisms 167 
that allow them to grow in macrophages. Additional mechanisms that include host immune 168 
dysregulation have been invoked to further render them hypervirulent [7]. Indeed, when we 169 
assessed the SA161 Beijing strain in a mouse aerosol infection model, we found it to be 170 
hypervirulent. Transient early increased bacterial burdens compared to H37Rv were associated 171 
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with early lethality (Supplementary Figure 3). Together these findings confirmed that SA161 has 172 
not only compensated for any macrophage growth defect due to the loss of Rv1258c but has 173 
further evolved additional mechanisms that renders it hypervirulent. Because multiple efflux 174 
pumps are reported to be upregulated in Beijing strains [12], we considered the possibility that 175 
the mechanisms that compensated for its early growth in macrophages might include the 176 
induction of other efflux pumps. Consistent with this possibility, we found that the bacterial 177 
efflux pump inhibitor verapamil inhibited SA161’s intramacrophage growth similarly to strains 178 
from other lineages [13](Figure 2B).  179 
 180 
DISCUSSION 181 
Our earlier studies showed that macrophage-induced drug tolerance is a potential contributor 182 
to the slow response of Mtb to antimicrobial treatment [2,3]. However, the findings were 183 
limited to laboratory strains belonging to a single Mtb lineage. This work shows that 184 
macrophage-induced drug tolerance is a feature of the other three predominant Mtb lineages 185 
as well. Moreover, the finding that the Beijing strains lack rifampin tolerance while retaining 186 
isoniazid tolerance corroborates our previous findings linking the efflux pump to the 187 
development of macrophage-induced rifampin tolerance [2]. 188 
 Our finding that the Beijing strains fail to develop macrophage-induced rifampin 189 
tolerance might be seen as presenting a potential quandary given that Beijing lineage TB is 190 
more likely to relapse after standard rifampin-containing regimens [14]. However, this 191 
increased propensity to relapse may simply be due to the compensated growth in macrophages 192 
and hypervirulence traits of the Beijing lineage, as we have shown here for SA161. Furthermore, 193 
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we demonstrate that treatment with the efflux pump inhibitor verapamil may inhibit 194 
intracellular growth of Beijing lineage strains even if they do not appear to develop 195 
macrophage-induced tolerance to rifampin.  196 
Our finding that the majority of Mtb lineages responsible for disease worldwide exhibit 197 
macrophage-induced tolerance to rifampin suggests that strategies to inhibit efflux mediated 198 
tolerance may be effective in shortening treatment regimens for the majority of patients. 199 
Although, Beijing strains do not demonstrate macrophage-induced tolerance to rifampin, efflux 200 
inhibition may still offer benefit for patients infected with these strains because verapamil and 201 
possibly other efflux pump inhibitors reduce the Beijing strains intramacrophage survival.   202 
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FIGURE LEGENDS: 203 
Figure 1: Macrophage induced tolerance to rifampin is common across clinical lineages of M. 204 
tuberculosis. A-D, THP-1 macrophages were infected with H37Rv (reference strain) or clinical 205 
strains as indicated and lysed at 2 hours (black bars) or 96 hours (white bars) post-infection. The 206 
released bacteria were treated for an additional 48 hours with 0.6 µg/ml isoniazid (A and B) or 207 
1 µg /ml rifampicin (C and D) prior to enumeration of colony-forming units (CFU). Results (A, C 208 
and D) are representative of three independent experiments and (B) is representative of two 209 
experiments. Error bars represent standard deviation. Significance testing was performed using 210 
T-test. 211 
 212 
Figure 2: Beijing lineage strains of M. tuberculosis are not compromised for early macrophage 213 
growth and are susceptible to intracellular verapamil treatment. A. THP-1 macrophages were 214 
infected with H37Rv or clinical strains of M. tuberculosis (MTB) as indicated and lysed at 2 hours 215 
(black bars) or 96 hours (white bars) and CFU enumerated at each time-point. B. THP-1 216 
macrophages were infected with MTB strains H37Rv, SA161, M4100A and SG1 for 48 hours and 217 
subsequently left untreated or treated for an additional 48 hours with 40 µg/ml verapamil (VER) 218 
prior to lysis and enumeration of CFU. Results (A) are representative of at least three 219 
independent experiments and (B) is representative of at least two experiments. Error bars 220 
represent standard deviation. Significance testing performed using T-test. 221 
  222 
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